In a major boost to its drug pipeline, Cardiol Therapeutics has bagged US patent protection for its heart-disease drug platform. 

The company announced a Notice of Allowance from the US Patent and Trademark Office for its application covering “Cannabidiol Compositions for Use in Treating Heart Conditions". 

Once issued, the patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38 across a wide range of inflammatory and fibrotic cardiac diseases through October 2040. 

The patent will cover the use of both therapies in treating or preventing multiple conditions—including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti-cancer drugs, and atherosclerosis—positioning the company for expanded clinical and commercial reach in the U.S., the world’s largest pharmaceutical market. 

“This important milestone extends our I.P. protection to the world’s largest pharmaceutical market,” said CEO David Elsley, calling the allowance a significant strengthening of the company’s competitive position. “With exclusivity through late 2040, we’re reinforcing the long-term value of our pipeline as we advance late-stage programs in recurrent pericarditis and acute myocarditis and prepare for first-in-human evaluation of CRD-38.” 

Chief Medical Officer Dr Andrew Hamer said the decision arrives at a strategically critical moment, following promising topline results from the company’s Phase II ARCHER trial of CardiolRx in acute myocarditis. Full data will be presented November 29 at the European Society of Cardiology meeting in Trieste. Hamer added that the patent creates room for new research avenues in myocarditis and strengthens prospects for CRD-38 in heart failure. 

Cardiol is currently running two major clinical programmes. The MAVERIC program is led by the ongoing Phase III trial evaluating CardiolRx for recurrent pericarditis, a painful inflammatory condition that often leads to repeated ER visits and hospitalizations. The therapy already holds Orphan Drug Designation from the US FDA. 

The ARCHER programme focuses on acute myocarditis, a leading cause of sudden cardiac death in people under 35. The completed Phase II study assessed the safety and efficacy of CardiolRx in this high-risk population. 

In parallel, the company is advancing CRD-38, designed for subcutaneous delivery to treat inflammatory heart disease and heart failure—a condition that costs the US healthcare system more than US$30 billion annually.